Michael F. Good

Q: What Schools Are Affiliated With Michael F. Good

Michael F. Good is affiliated with the following schools: University of Queensland, Albany Medical College, Griffith University, University of Alberta

Michael F. Good's AcademicInfluence.com Rankings

Michael F. Good

Philosophy

#7774

World Rank

#11029

Historical Rank

Logic

#4810

World Rank

#6139

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Michael F. Good Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael F. Good was the Director of the Queensland Institute of Medical Research, from 2000 to 2010. He was Chair of the National Health and Medical Research Council. He graduated from the Queensland University Medical School in 1978. He later undertook further training in medical research at the Walter and Eliza Hall Institute of Medical Research in Melbourne.

(See a Problem?)

Michael F. Good's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

New Generation Vaccines (1990) (676)
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum (2002) (431)
Malaria vaccine developments (2004) (215)
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes (1990) (208)
Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. (2005) (202)
Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effect (1997) (199)
A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. (2007) (191)
The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. (1987) (186)
Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. (2003) (183)
Pathways and strategies for developing a malaria blood-stage vaccine. (1998) (178)
Immune-Mediated Mechanisms of Parasite Tissue Sequestration during Experimental Cerebral Malaria (2010) (167)
Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum (1988) (165)
New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population (2000) (155)
The Mechanism and Significance of Deletion of Parasite-specific CD4+ T Cells in Malaria Infection (2002) (151)
Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. (2010) (149)
Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. (1997) (146)
Towards a blood-stage vaccine for malaria: are we following all the leads? (2001) (136)
Protein Antigenic Structures Recognized by T Cells; Potential Applications to Vaccine Design (1987) (132)
Immune effector mechanisms in malaria. (1999) (131)
PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria. (2013) (129)
The relevance of non-human primate and rodent malaria models for humans (2011) (126)
Status of research and development of vaccines for Streptococcus pyogenes. (2016) (122)
Immunity to asexual blood stage malaria and vaccine approaches (2002) (115)
Challenges and strategies for developing efficacious and long-lasting malaria vaccines (2019) (112)
Nanovaccines and their mode of action. (2013) (112)
Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies (1989) (106)
Malaria vaccine design: immunological considerations. (2010) (104)
Prolonged Th1‐like response generated by a Plasmodium yoeli‐specific T cell clone allows complete clearance of infection in reconstituted mice (1997) (104)
Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. (1994) (102)
Controlled Human Malaria Infection: Applications, Advances, and Challenges (2017) (100)
Plasmodium Strain Determines Dendritic Cell Function Essential for Survival from Malaria (2007) (94)
What really happens to dendritic cells during malaria? (2008) (93)
Vaccine-induced immunity to malaria parasites and the need for novel strategies. (2005) (93)
Plasmodium yoelii Can Ablate Vaccine-Induced Long-Term Protection in Mice1 (2005) (92)
Interdependence of CD4+ T cells and malarial spleen in immunity to Plasmodium vinckei vinckei. Relevance to vaccine development. (1989) (91)
Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci (1994) (91)
Heterologous Immunity in the Absence of Variant-Specific Antibodies after Exposure to Subpatent Infection with Blood-Stage Malaria (2005) (89)
Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria (2013) (87)
A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. (2011) (87)
‘Natural’ T cells responsive to malaria: evidence implicating immunological cross-reactivity in the maintenance of TCRαβ+ malaria-specific responses from non-exposed donors (1992) (87)
Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies. (1992) (87)
Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. (1997) (86)
Immunity to sexual stages of malaria parasites. (1988) (84)
Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. (1996) (81)
Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. (1999) (79)
Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. (1990) (79)
High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. (2005) (78)
Apoptotic Deletion of Th Cells Specific for the 19-kDa Carboxyl-Terminal Fragment of Merozoite Surface Protein 1 During Malaria Infection1 (2001) (76)
Cross-species malaria immunity induced by chemically attenuated parasites. (2013) (75)
Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. (2010) (74)
Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. (2011) (72)
What have we learnt from mouse models for the study of malaria? (2009) (71)
Malaria parasite‐specific Th1‐like T cells simultaneously reduce parasitemia and promote disease (1999) (70)
Surges of Increased T Cell Reactivity to an Encephalitogenic Region of Myelin Proteolipid Protein Occur More Often in Patients with Multiple Sclerosis Than in Healthy Subjects1 (2000) (68)
Prospective Surveillance of Streptococcal Sore Throat in a Tropical Country (2009) (67)
Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. (2006) (67)
Potential of Lipid Core Peptide Technology as a Novel Self-Adjuvanting Vaccine Delivery System for Multiple Different Synthetic Peptide Immunogens (2003) (64)
Mapping a conserved conformational epitope from the M protein of group A streptococci. (1996) (63)
Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. (1997) (63)
High frequency of malaria‐specific T cells in non‐exposed humans (1992) (61)
Geographically restricted heterogeneity of the Plasmodium falciparum circumsporozoite protein: relevance for vaccine development (1992) (60)
Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice (2011) (60)
Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines (2020) (59)
emm and C-Repeat Region Molecular Typing of Beta-Hemolytic Streptococci in a Tropical Country: Implications for Vaccine Development (2009) (59)
The immunological challenge to developing a vaccine to the blood stages of malaria parasites (2004) (59)
Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis (2003) (58)
Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. (2008) (58)
A Lipid Core Peptide Construct Containing a Conserved Region Determinant of the Group A Streptococcal M Protein Elicits Heterologous Opsonic Antibodies (2002) (58)
Escaping the immune system: How the malaria parasite makes vaccine development a challenge. (2013) (57)
Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus. (2018) (57)
Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. (1989) (56)
Interactions between malaria parasites and the host immune system. (2005) (56)
Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. (2003) (56)
Location of human cytotoxic T cell epitopes within a polymorphic domain of the Plasmodium falciparum circumsporozoite protein. (1991) (56)
Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. (2002) (56)
Promiscuous malaria peptide epitope stimulates CD45Ra T cells from peripheral blood of nonexposed donors. (1992) (55)
Whole parasite blood stage malaria vaccines: A convergence of evidence (2010) (55)
Human T clones reactive to the sexual stages of Plasmodium falciparum malaria. High frequency of gamete-reactive T cells in peripheral blood from nonexposed donors. (1987) (54)
Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus. (2016) (54)
Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens. (1989) (54)
Low-level Plasmodium falciparum blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers. (2012) (54)
Current Approaches to Group A Streptococcal Vaccine Development (2016) (53)
Mechanism of Protection Induced by Group A Streptococcus Vaccine Candidate J8-DT: Contribution of B and T-Cells Towards Protection (2009) (53)
Epidemiological Analysis of Non-M-Typeable Group A Streptococcus Isolates from a Thai Population in Northern Thailand (2000) (53)
Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus. (2016) (53)
Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge (1998) (52)
Analysis of human T cell clones specific for conserved peptide sequences within malaria proteins. Paucity of clones responsive to intact parasites. (1994) (52)
‘Original antigenic sin’, T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion (1993) (51)
The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria (2003) (50)
CD4+ T Cells Acting Independently of Antibody Contribute to Protective Immunity to Plasmodium chabaudi Infection After Apical Membrane Antigen 1 Immunization1 (2000) (50)
Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. (2005) (50)
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. (2003) (49)
Prospective Surveillance of Invasive Group A Streptococcal Disease, Fiji, 2005–2007 (2009) (49)
Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. (2009) (49)
Antigens released at schizont burst stimulate Plasmodium falciparum-specific CD4+ T cells from non-exposed donors: potential for cross-reactive memory T cells to cause disease. (1995) (49)
Functional clonal deletion of cytotoxic T-lymphocyte precursors in chimeric thymus produced in vitro from embryonic Anlagen. (1983) (49)
Intranasal immunization with yeast‐expressed 19 kD carboxyl‐terminal fragment of Plasmodium yoelii merozoite surface protein‐1 (yMSP119) induces protective immunity to blood stage malaria infection in mice (1998) (48)
Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. (1994) (47)
Iron status and cellular immune competence. (1988) (47)
Immunological Evaluation of Lipopeptide Group A Streptococcus (GAS) Vaccine: Structure-Activity Relationship (2012) (46)
A Synthetic M Protein Peptide Synergizes with a CXC Chemokine Protease To Induce Vaccine-Mediated Protection against Virulent Streptococcal Pyoderma and Bacteremia (2015) (46)
Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. (2015) (46)
Malaria parasites up close (2006) (45)
Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial (2018) (45)
Long-Term Antibody Memory Induced by Synthetic Peptide Vaccination Is Protective against Streptococcus pyogenes Infection and Is Independent of Memory T Cell Help (2013) (45)
Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines. (2014) (45)
CD8+ T Lymphocyte-Mediated Loss of Marginal Metallophilic Macrophages following Infection with Plasmodium chabaudi chabaudi AS1 (2006) (44)
Major population differences in T cell response to a malaria sporozoite vaccine candidate. (1990) (44)
Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery. (2016) (44)
Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. (2006) (43)
A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. (1997) (43)
T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: relevance to vaccine development (1993) (43)
Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70 (1993) (43)
Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. (2004) (43)
Antigenic diversity in Plasmodium falciparum. (1988) (43)
Lack of cross-reactivity between variant T cell determinants from malaria circumsporozoite protein. (1988) (42)
Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. (2010) (42)
Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models (2016) (42)
Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid‐core peptide technology (2002) (41)
Effect of initial treatment of chronic inflammatory periodontal disease on the frequency of peripheral blood T-lymphocytes specific to periodontopathic bacteria. (1991) (41)
Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation (2017) (40)
Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria (1998) (40)
Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). (2013) (40)
Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. (2014) (40)
Systemic Tumor Necrosis Factor Generated during Lethal Plasmodium Infections Impairs Dendritic Cell Function1 (2007) (39)
Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness (1994) (39)
Cytotoxic T lymphocyte (CTL) low-responsiveness to the Plasmodium falciparum circumsporozoite protein in naturally-exposed endemic populations: analysis of human CTL response to most known variants. (1993) (39)
Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant. (2014) (39)
Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines (2015) (38)
Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. (2012) (38)
Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity. (2014) (38)
Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci (2016) (37)
Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus. (2016) (37)
Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. (2006) (37)
M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. (2005) (37)
Do immigrant outflows lead to native inflows? An empirical analysis of the migratory responses to US state immigration legislation (2013) (36)
Protective and Nonprotective Epitopes from Amino Termini of M Proteins from Australian Aboriginal Isolates and Reference Strains of Group A Streptococci (2000) (35)
Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. (2006) (34)
Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. (2005) (34)
Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. (2008) (34)
Immunoglobulin G3 Antibodies Specific for the 19-Kilodalton Carboxyl-Terminal Fragment of Plasmodium yoelii Merozoite Surface Protein 1 Transfer Protection to Mice Deficient in Fc-γRI Receptors (2000) (33)
A case for whole-parasite malaria vaccines. (2007) (32)
Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. (2010) (32)
Analysis of true anti-hapten cytotoxic clones in limit dilution microcultures after correction for "anti-self" activity: precursor frequencies, Ly-2 and Thy-1 phenotype, specificity, and statistical methods. (1983) (32)
Limit dilution analysis of peripheral blood T lymphocytes specific to periodontopathic bacteria. (1989) (31)
An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system. (2013) (31)
Malaria's journey through the lymph node. (2007) (31)
Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. (1999) (31)
Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci (2015) (30)
Development of immunity to malaria may not be an entirely active process (1995) (29)
Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma (2016) (29)
Whole organism blood stage vaccines against malaria. (2015) (29)
Dendritic cell biology during malaria (2007) (29)
'Natural' T cells responsive to malaria: evidence implicating immunological cross-reactivity in the maintenance of TCR alpha beta+ malaria-specific responses from non-exposed donors. (1992) (28)
Identification of Caucasian CD4 T cell epitopes on the circumsporozoite protein of Plasmodium vivax. T cell memory. (1993) (28)
Identification and assessment of new vaccine candidates for group A streptococcal infections. (2004) (28)
Evidence for limited activation of distinct CD4+ T cell subsets in response to the Plasmodium falciparum circumsporozoite protein in Papua New Guinea (1994) (27)
Method for the synthesis of highly pure vaccines using the lipid core peptide system (2006) (27)
Defying malaria: Arming T cells to halt malaria (2011) (27)
Towards understanding the pathogenesis of rheumatic fever. (1996) (27)
The immunologic significance of variation within malaria circumsporozoite protein sequences. (1989) (27)
The effect of experimental iron-overload on splenic T cell function: analysis using cloning techniques. (1987) (26)
The implications for malaria vaccine programs if memory T cells from non-exposed humans can respond to malaria antigens. (1991) (26)
Strategies in the development of vaccines to prevent infections with group A streptococcus (2013) (26)
Human and murine CD4 T cell epitopes map to the same region of the malaria circumsporozoite protein: limited immunogenicity of sporozoites and circumsporozoite protein. (1988) (25)
Protection of rats against malaria by a transplanted immune spleen (1996) (25)
Immune response to superoxide dismutase in group A streptococcal infection. (2004) (25)
Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. (2005) (25)
Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study (2018) (24)
Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus. (2017) (24)
A semi-synthetic whole parasite vaccine designed to protect against blood stage malaria. (2016) (24)
Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. (2007) (24)
The hope but challenge for developing a vaccine that might control malaria (2009) (24)
Novel platform technology for modular mucosal vaccine that protects against streptococcus (2016) (24)
Nonessential Research in the New Normal: The Impact of COVID-19 (2020) (24)
Identification of T Cell Epitopes on the 33-kDa Fragment of Plasmodium yoelii Merozoite Surface Protein 1 and Their Antibody-Independent Protective Role in Immunity to Blood Stage Malaria1 (2002) (23)
Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. (2019) (23)
Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates. (2016) (23)
Lipoamino acid-based adjuvant carrier system: enhanced immunogenicity of group a streptococcal peptide epitopes. (2002) (23)
Chemically Attenuated Blood-Stage Plasmodium yoelii Parasites Induce Long-Lived and Strain-Transcending Protection (2016) (23)
Polymorphism in the circumsporozoite (CS) protein of Plasmodium falciparum. (1989) (22)
Analysis of Immunological Nonresponsiveness to the 19-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium yoelii: Rescue by Chemical Conjugation to Diphtheria Toxoid (DT) and Enhancement of Immunogenicity by Prior DT Vaccination (2003) (22)
Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197 (2013) (22)
A whole parasite vaccine to control the blood stages of Plasmodium: the case for lateral thinking. (2011) (22)
Plasmodium falciparum-specific T cell clones from non-exposed and exposed donors are highly diverse in TCR beta chain V segment usage. (1996) (22)
Identification of T Cell Epitopes on the 33-kDa Fragment of Plasmodium yoelii Merozoite Surface Protein 1 and Their Antibody-Independent Protective Role in Immunity to Blood Stage Malaria (2002) (21)
Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge. (2002) (21)
Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation (2017) (21)
A malaria vaccine strategy based on the induction of cellular immunity. (1992) (21)
Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage. (2004) (21)
Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease (2006) (21)
Development of highly pure α-helical lipoglycopeptides as self-adjuvanting vaccines (2009) (21)
Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. (2006) (21)
The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus. (2016) (21)
Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. (2008) (21)
Immunological Response to Parenteral Vaccination with Recombinant Hepatitis B Virus Surface Antigen Virus-Like Particles Expressing Helicobacter pylori KatA Epitopes in a Murine H. pylori Challenge Model (2011) (21)
Vaccination Against Rheumatic Heart Disease: A Review of Current Research Strategies and Challenges (2012) (21)
The Impact of Established Immunoregulatory Networks on Vaccine Efficacy and the Development of Immunity to Malaria (2016) (20)
M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus. (2013) (20)
Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. (2008) (20)
Humanized Mouse Models to Study Cell-Mediated Immune Responses to Liver-Stage Malaria Vaccines. (2015) (19)
Functional clonal deletion and suppression as complementary mechanisms operative in adult hapten-induced cytotoxic T cell tolerance. (1983) (19)
Examining cellular immune responses to inform development of a blood-stage malaria vaccine (2016) (19)
Design and Synthesis of Lipopeptide–Carbohydrate Assembled Multivalent Vaccine Candidates Using Native Chemical Ligation (2009) (19)
Nature and Specificity of the Required Protective Immune Response That Develops Postchallenge in Mice Vaccinated with the 19-Kilodalton Fragment of Plasmodium yoelii Merozoite Surface Protein 1 (2002) (19)
The importance of T cell homing and the spleen in reaching a balance between malaria immunity and immunopathology: The moulding of immunity by early exposure to cross‐reactive organisms (1992) (19)
Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins. (1997) (19)
A study of human T-cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein (1996) (18)
Gold(i) phosphine compounds as parasite attenuating agents for malaria vaccine and drug development. (2018) (18)
Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes. (1991) (18)
The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic (2020) (18)
Vaccine development for group A streptococcus infections and associated disease. (2004) (18)
Characterization of the Antibody Response against Plasmodium falciparum Erythrocyte Membrane Protein 1 in Human Volunteers (2007) (18)
Profoundly Reduced CD1c+ Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection (2016) (18)
Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites. (1997) (17)
Linear and branched polyacrylates as a delivery platform for peptide-based vaccines. (2016) (17)
Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes (1990) (17)
Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial (2017) (17)
A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy (1997) (17)
Contribution of cryptic epitopes in designing a group A streptococcal vaccine (2018) (16)
A lipophilic adjuvant carrier system for antigenic peptides (2001) (16)
Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines (2019) (16)
Inhibition of 19-kDa C-Terminal Region of Merozoite Surface Protein-1-Specific Antibody Responses in Neonatal Pups by Maternally Derived 19-kDa C-Terminal Region of Merozoite Surface Protein-1-Specific Antibodies but Not Whole Parasite-Specific Antibodies1 (2004) (16)
A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study. (2021) (15)
Clones of cytotoxic T lymphocytes reactive to haptenated allogeneic cells: precursor frequency and characteristics as determined by a split-culture approach. (1983) (15)
A technique for the synthesis of highly-pure, mono-epitopic, multi-valent lipid core peptide vaccines (2007) (15)
Prospecting for new group A streptococcal vaccine candidates. (2004) (15)
Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate (2016) (15)
Neonatal exposure to immunogenic peptides. Differential susceptibility to tolerance induction of helper T cells and B cells reactive to malarial circumsporozoite peptide epitopes. (1988) (15)
Immunological responses from non-exposed donors to malaria antigens: implications for immunity and pathology. (1994) (15)
Vaccine strategies to prevent rheumatic fever (1999) (15)
Malaria vaccines: the case for a whole-organism approach (2008) (14)
Rheumatic heart disease: A review of the current status of global research activity. (2020) (14)
Diversity in the circumsporozoite protein of Plasmodium vivax: Does it matter? (1995) (14)
The Role of the 19-kDa Region of Merozoite Surface Protein 1 and Whole-Parasite-Specific Maternal Antibodies in Directing Neonatal Pups’ Responses to Rodent Malaria Infection1 (2003) (14)
Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. (2004) (14)
The effect of iron (Fe3+) on the cloning efficiency of human memory T4+ lymphocytes. (1986) (14)
Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy (2018) (14)
Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen (2017) (13)
M protein typing of Thai group A streptococcal isolates by PCR-Restriction fragment length polymorphism analysis (2005) (13)
Analysis of circumsporozoite protein-specific immune responses following recent infection with Plasmodium vivax. (2004) (13)
The effect of non-transferrin-bound iron on murine T lymphocyte subsets: analysis by clonal techniques. (1987) (13)
Our impasse in developing a malaria vaccine (2011) (13)
T-cell antigens and epitopes in malaria vaccine design. (1990) (12)
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria (2009) (12)
Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite (2016) (12)
Antibodies to Cryptic Epitopes in Distant Homologues Underpin a Mechanism of Heterologous Immunity between Plasmodium vivax PvDBP and Plasmodium falciparum VAR2CSA (2019) (12)
Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine (2017) (12)
Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites (2018) (12)
Identification of early cellular immune factors regulating growth of malaria parasites in humans. (2005) (12)
Cross-Species Immune Recognition Between Plasmodium vivax Duffy Binding Protein Antibodies and the Plasmodium falciparum Surface Antigen VAR2CSA (2018) (12)
Malaria vaccines: the case for a whole-organism approach. (2008) (12)
Experimental asexual blood stage malaria immunity. (1999) (11)
Antibody levels to the class I and II epitopes of the M protein and myosin are related to group A streptococcal exposure in endemic populations. (2001) (11)
Group A Streptococcal Vaccine Candidates based on the Conserved Conformational Epitope from M Protein (2011) (11)
Persistence and immunogenicity of chemically attenuated blood stage Plasmodium falciparum in Aotus monkeys. (2016) (11)
Pre-clinical evaluation of a whole-parasite vaccine to control human babesiosis. (2021) (11)
Mixed results for a malaria vaccine (2011) (10)
Vaccines Against Human Hookworm Disease (2004) (10)
Summary of the meeting on cellular mechanisms in malaria immunity. (1990) (10)
Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea. (2005) (10)
Molecular analysis of T and B cell repertoires in mice immunized with Opisthorchis viverrini antigens. (1991) (10)
Effect of Plasmodium yoelii Exposure on Vaccination with the 19-Kilodalton Carboxyl Terminus of Merozoite Surface Protein 1 and Vice Versa and Implications for the Application of a Human Malaria Vaccine (2008) (10)
Soluble CD38 significantly prolongs the lifespan of memory B‐cell responses (2008) (9)
Antigenic diversity and MHC genetics in sporozoite immunity. (1994) (9)
Synthesis, Characterization and Immunological Evaluation of Self‐Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties (2017) (9)
Whole parasite vaccines for the asexual blood stages of Plasmodium (2019) (9)
Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria. (2002) (9)
Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood. (1984) (9)
Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice (2019) (9)
Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25. (1995) (8)
Ambient Temperature Stable, Scalable COVID‐19 Polymer Particle Vaccines Induce Protective Immunity (2021) (8)
Towards the development of the ideal malaria vaccine: A decade of progress in a difficult field (1991) (8)
Cryptic epitope for antibodies should not be forgotten in vaccine design (2016) (8)
Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection (2003) (8)
Pasteur Approach to a Malaria Vaccine May Take the Lead (2013) (8)
Plasmodium berghei bio-burden correlates with parasite lactate dehydrogenase: application to murine Plasmodium diagnostics (2016) (8)
Comparison of Fluorinated and Nonfluorinated Lipids in Self-Adjuvanting Delivery Systems for Peptide-Based Vaccines. (2017) (8)
Interpreting challenge data from early phase malaria blood stage vaccine trials (2018) (8)
Poly-L-lysine-coated nanoparticles are ineffective in inducing mucosal immunity against group a streptococcus (2017) (8)
Plasmodium falciparum CS protein--prime malaria vaccine candidate: definition of the human CTL domain and analysis of its variation. (1992) (8)
The immune response to asexual blood stages of malaria parasites. (1998) (8)
Correlation between Bioluminescence and Bacterial Burden in Passively Protected Mice Challenged with a Recombinant Bioluminescent M49 Group A Streptococcus Strain (2009) (7)
Mannosylated liposomes formulated with whole parasite P. falciparum blood-stage antigens are highly immunogenic in mice. (2019) (7)
Dactylosporangium luridum sp. nov., Dactylosporangium luteum sp. nov. and Dactylosporangium salmoneum sp. nov., nom. rev., isolated from soil (2013) (7)
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2 (2021) (7)
Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes (2021) (7)
Characteristics of tolerance induction among adult hapten-specific T lymphocyte precursors revealed by clonal analysis. (1983) (7)
Effect of polymorphism of sporozoite antigens on T-cell activation. (1994) (7)
Synthesis and Immunological Evaluation of M Protein Targeted Tetra-Valent and Tri-Valent Group A Streptococcal Vaccine Candidates Based on the Lipid-Core Peptide System (2006) (7)
Exploiting the apicoplast: apicoplast-targeting drugs and malaria vaccine development. (2017) (7)
M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP) (2020) (7)
Streptococcus: An organism causing diseases beyond neglect (2020) (6)
Polyspecific malaria antibodies present at the time of infection inhibit the development of immunity to malaria but antibodies specific for the malaria merozoite surface protein, MSP1, facilitate immunity (2002) (6)
Assessment of human cytotoxic T cell activity using synthetic peptides: potential for field application. (1991) (6)
Malaria vaccines: New hope in old ideas (2006) (6)
Malaria: Tying the conductor's arms (1999) (6)
Gravity and Localized Migration (2013) (5)
Can class I epitope of M protein be a diagnostic marker for rheumatic fever in populations endemic for group A streptococci? (1998) (5)
A method for analysing the clonal precursors of concanavalin A-induced suppressor cells. (1985) (5)
Evaluation of the 2-Aminomethylphenol JPC-2997 in Aotus Monkeys Infected with Plasmodium falciparum (2015) (5)
Cellular interactions of covR/S mutant group A Streptococci. (2017) (5)
Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation (2018) (5)
Malaria-specific memory T cells: putative roles of different types of memory responses in immunity and disease. (1994) (5)
Coordinated Strategy for a Model-Based Decision Support Tool for Coronavirus Disease, Utah, USA (2021) (5)
Development of lipid-core-peptide (LCP) based vaccines for the prevention of group A streptococcal (GAS) infection (2003) (5)
Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8. (2018) (5)
The quest for GAS vaccine (2015) (4)
Malaria vaccine research: lessons from 2008/9. (2009) (4)
Back to the future for antiparasite vaccines? (2013) (4)
A whole parasite transmission-blocking vaccine for malaria: an ignored strategy (2017) (4)
Vaccinating Children against COVID-19: Commentary and Mathematical Modeling (2022) (4)
Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines (2021) (4)
Platelets Kill the Parasite Within (2012) (3)
IL-2 and IL-4 can co-modulate the generation of cytotoxic T cells through CD8- CD4- splenic lymphocytes. (1989) (3)
New Generation Vaccines, Fourth Edition (2004) (3)
The Ability to Inoculate Purified Malaria Sporozoites Will Accelerate Vaccine and Drug Discovery (2014) (3)
Development and Evaluation of a Cryopreserved Whole-Parasite Vaccine in a Rodent Model of Blood-Stage Malaria (2021) (3)
In Search of the Holy Grail: A Specific Diagnostic Test for Rheumatic Fever (2021) (3)
Plasmodium infection and drug cure for malaria vaccine development (2021) (3)
Chinese National Strategy of Total War (2008) (3)
Generation of a Peptide Vaccine Candidate against Falciparum Placental Malaria Based on a Discontinuous Epitope (2020) (3)
Immunological Impediments to Developing a Blood Stage Malaria Vaccine (2006) (3)
Immunity to Blood Stage Malaria Antibody-Independent Protective Role in Merozoite Surface Protein 1 and Their Plasmodium yoelii 33-kDa Fragment of Identification of T Cell Epitopes on the (2002) (3)
A vaccine for human babesiosis: prospects and feasibility. (2022) (3)
Intranasal immunisation of mice with a streptococcal peptide-based vaccine. (1997) (2)
Plasmodium falciparum Asexual Blood Stage Vaccine Candidates: current Status (2004) (2)
Combinatorial liposomal peptide vaccine induces IgA and confers protection against influenza virus and bacterial super‐infection (2021) (2)
Human T-cell responses to malaria: mostly forgotten or committed to memory? (1994) (2)
New Generation Vaccines, 3rd Edition (2004) (2)
Ambient Temperature Stable, Scalable COVID‐19 Polymer Particle Vaccines Induce Protective Immunity (Adv. Healthcare Mater. 3/2022) (2022) (2)
Functional clonal deletion and suppression as complementary mechanisms in T lymphocyte tolerance. (1986) (2)
How Localized is the Pro-trade Effect of Immigration? Evidence from Mexico and the United States (2012) (2)
Cell trafficking. Malaria blood-stage parasite-specific CD4+ T cells after adoptive transfer into mice. (2002) (2)
Development of Peptide Vaccines against HPV-16 Associated Cervical Cancer and Group A Streptococci (2006) (2)
Decreased expression of the apoptosis inhibitor Bcl-2 in T cells in the central nervous system in experimental autoimmune encephalomyelitis (1996) (1)
Disarming the malaria parasite (2008) (1)
A Superficial Skin Scarification Method in Mice to Mimic Streptococcus pyogenes Skin Infection in Humans. (2020) (1)
The development of vaccines to prevent rheumatic fever (2002) (1)
Malaria vaccine development: recent progress towards a sporozoite vaccine. (1990) (1)
David James Kemp 1945–2013 (2014) (1)
ANTIGENIC DIVERSITY IN P.FALCIPARUM (1988) (1)
Development of Vaccines for Ebola and Marburg Viruses: Efficacy and Regulatory Considerations (2009) (1)
The Search for Major Plagge : The Nazi Who Saved Jews (2006) (1)
Investigation of the factors affecting catabolism of antibodies raised against a vaccine candidate based on the conserved region of the M-protein (2006) (1)
A method for the accurate determination of anti-hapten cytotoxic T lymphocyte precursors: correction for apparent 'anti-self' reactivity. (1982) (1)
Towards the synthesis of a highly pure, multiepitopic, mucosal group A streptococcal lipopeptide vaccine (2006) (1)
Biological strategies and political hurdles in developing malaria vaccines (2021) (1)
Multi-layer engineered nanoliposomes as a novel tool for oral delivery of lipid core peptide-based vaccines against group A streptococcus ( GAS ) (2015) (1)
Surface Protein-1 Carboxyl-Terminal Fragment of Merozoite Acquired with Antibodies to the 19-kDa Passively Plasmodium yoelii Immunity to Response Involving B Cells and Th Cells in Absolute Requirement for an Active Immune (1999) (1)
The Rise of Human Babesiosis and the Urgent Need for Improved Detection and a Vaccine (2019) (1)
A case of 'hit-and-run' in Plasmodium genetics. (2006) (1)
Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines. (2022) (1)
A lipophilic adjuvant carrier system for antigenic peptides (2004) (1)
Navigating commercial approval of therapeutics: The evolution of the United States Food and Drug (2015) (1)
Pre-erythrocytic and asexual erythrocytic stage whole-organism malaria vaccines (2010) (1)
An Evaluation of the Impact of Hopwood on Minority Enrollment at the University of Texas at Austin (2007) (1)
Prospects for a vaccine against malaria (2002) (1)
Peptide analysis of the T cell response to the malaria circumsporozoite (CS) protein. (1990) (1)
Experimental Asexual Blood Stage Malaria Immunity (1999) (1)
Is Independent of Memory T Cell Help Infection and Streptococcus pyogenes against Synthetic Peptide Vaccination Is Protective Long-Term Antibody Memory Induced by (2013) (0)
The lipid core peptide system in vaccine delivery (2006) (0)
Streptolysin O Deficiency in Streptococcus pyogenes M1T1 covR/S Mutant Strain Attenuates Virulence in In Vitro and In Vivo Infection Models (2023) (0)
Vaccine design against streptococcal infection (2003) (0)
Vaccine-Induced Long-Term Protection in Can Ablate Plasmodium yoelii (2005) (0)
Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP). (2020) (0)
Synthetic vaccines: Enhanced immunogenicity of Streptococcus peptide epitopes. (2001) (0)
Plasmodium berghei bio-burden correlates with parasite lactate dehydrogenase: application to murine Plasmodium diagnostics (2016) (0)
Lipid-core-peptides for vaccination: Structure-activity relationship (2002) (0)
This information is current as Super Immunogen Complex Synthetic Peptide To Become a Enhancing Vaccine Efficacy by Engineering a (2017) (0)
Lipids and sugars: Application for peptide delivery and for enhancing synthetic peptide immunogenicity (2001) (0)
Vaccine delivery utilizing liposaccharides (2007) (0)
The synthesis and immunological activity of a lipid-core peptide (LCP) based Human Papillomavirus (HPV) type-16 vaccine (2005) (0)
Multi-epitopic lipid core peptide vaccine with broad protective immune responses against Group A streptococcus (2006) (0)
Targeting the NS 5 Protein of Zika Virus (2016) (0)
Essays on Migration: Nexus with Policy, Trade, and Development (2014) (0)
Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation (2017) (0)
Vaccination and autoimmunity (2004) (0)
Induction of anti-Plasmodium immunity following subpatent infection with live erythrocytic stages and drug cure. (2013) (0)
A novel immunoadjuvant carrier system for synthetic peptides (2002) (0)
Fluctuations in the frequencies of circulating myelin-reactive T cells in healthy subjects and patients with multiple sclerosis (1999) (0)
The development of a live vaccine for the delivery of a minimal conformational protective epitope (2008) (0)
MAM 2020: Growing Strong on the 20th Anniversary. (2020) (0)
Antigen experienced and memory T cell correlates of protection in peripheral blood following administration of a whole parasite blood stage malaria vaccine (P4479) (2013) (0)
M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP). (2020) (0)
Peptide-Protein Conjugation and Characterization to Develop Vaccines for Group A Streptococcus. (2021) (0)
A Conformationally optimised recombinant vaccine against Group A streptococcus (2007) (0)
Development of a Multivalent Heteroepitopic Group A Streptococcus Vaccine (2007) (0)
Lipid-core-peptides for vaccination: A structure-activity relationship study. (2001) (0)
Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum : Immunodominant T-cell domains map to the polymorphic regions of the molecule ( malaria / vaccines ) (2003) (0)
Vaccine delivery: synthesis and investigation of a highly pure, multi-epitopic lipopeptide vaccine candidate. (2009) (0)
A multiple antigen lipophilic adjuvant carrier system (MALAC) (2002) (0)
Lipid and carbohydrate based macromolecules in drug and vaccine delivery (2003) (0)
Liposaccharides in Peptide Vaccine Delivery (2007) (0)
Liposaccharides in peptide, gene and vaccine delivery (2006) (0)
Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model (2023) (0)
Vaccine delivery utilizing liposaccharides. (2009) (0)
Infection Merozoite Surface Protein 1 During Malaria 19-kDa Carboxyl-Terminal Fragment of Apoptotic Deletion of Th Cells Specific for the Good (2001) (0)
Malaria vaccines. (1992) (0)
Immunogenicity of recombinant polytope constructs containing protective group A streptococcal antigens, J14 and H12 (2006) (0)
The importance of epitope and lipid orientation in the design of synthetic self-adjuvanting group A streptococcal (GAS) vaccine (2007) (0)
Synthetic vaccines containing multiple copies of group A streptococcus peptide epitopes. (2001) (0)
Lipid-core-peptides for vaccination. (2001) (0)
Liposomal mucosal vaccine delivery system: Immunogenicity, inflammatory response and protection from group A Streptococcus challenge (2016) (0)
T-cell immunity to malaria (1994) (0)
Plasmodium following Infection with Marginal Metallophilic Macrophages T Lymphocyte-Mediated Loss of + CD 8 (2006) (0)
Enhanced immunogenicity of group A streptococcal peptide epitopes by lipoamino acid based adjuvant carrier system. (2001) (0)
Healthy Subjects Patients with Multiple Sclerosis Than in Proteolipid Protein Occur More Often in Encephalitogenic Region of Myelin Surges of Increased T Cell Reactivity to an (2000) (0)
Vaccine Control Strategies against Group A Streptococcal Infections (2004) (0)
Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP) (2020) (0)
A vaccine to provide strain-transcending immunity to group A streptococci (2011) (0)
David James Kemp OAM FAA (1945–2013) (2014) (0)
Faculty Opinions recommendation of Escape of malaria parasites from host immunity requires CD4+ CD25+ regulatory T cells. (2004) (0)
Faculty Opinions recommendation of Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. (2003) (0)
Impairs Dendritic Cell Function Infections Plasmodium during Lethal Systemic Tumor Necrosis Factor Generated (2012) (0)
Blood T-cell reactivity to gangliosides GM3 and GQ1b is increased in patients with primary progressive multiple sclerosis (2002) (0)
Vaccine delivery: Synthesis and investigation of a highly pure, multi-epitopic lipopeptide vaccine candidate (2007) (0)
Synthetic peptides and vaccines which contain these (1995) (0)
Development of vaccines to prevent Group A streptococcal infections and rheumatic fever (2010) (0)
Development of totally synthetic self-adjuvanting vaccines against Group A streptococcus (2006) (0)
Polyphenylalanine as a self-adjuvanting delivery system for peptide-based vaccines: the role of peptide conformation (2022) (0)
The Mechanism and Signiﬁcance of Deletion of Parasite-speciﬁc CD4 (cid:2) T Cells in Malaria Infection (2002) (0)
Intranasal vaccination with a lipopeptide containing a minimal, conserved M-protein derived peptide and a self-adjuvanting lipid induces both systemic and mucosal immune responses in mice (2006) (0)
Investigation of liposomal self-adjuvanting peptide epitopes derived from conserved blood-stage Plasmodium antigens (2022) (0)
Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial (2017) (0)
Exploring the potential for dual vaccination against Hepatitis B virus and Helicobacter pylori using a recombinant virus like particle (2006) (0)
Historical review: Sir Gustav Nossal--immunologist and more. (2004) (0)
Parasite-Specific Antibodies Protein-1-Specific Antibodies but Not Whole Region of Merozoite Surface Maternally Derived 19-kDa C-Terminal Antibody Responses in Neonatal Pups by Merozoite Surface Protein-1-Specific Inhibition of 19-kDa C-Terminal Region of (2004) (0)
Peptide-lipid-carbohydrate based vaccine against group A Streptococcal infection. (2007) (0)
Clones of cytotoxic T lymphocytes : allogeneic cells: Precursor frequen4 as determined by a split-culture ap) (allo-restricted T cells/allo-reactive T cells/limit-dilution cultures/ha (2016) (0)
Towards understanding the pathogenesis of rheumatic fever. Commentary (1996) (0)
lance of malaria that will be invaluable for vaccine and possibly drug development to combat malaria. (2005) (0)
Corrigendum to "A Study Of Human T-Cell Lines Generated From Multiple Sclerosis Patients And Controls By Stimulation With Peptides Of Myelin Basic Protein" (J. Neuroimmunol. 70, 65-74) (1997) (0)
Human T cell responses to myelin basic protein isoforms (1993) (0)
Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines (2015) (0)
Antibodies to Cryptic Epitopes in Distant Homologues Underpin a Mechanism of Heterologous Immunity between Plasmodium vivax PvDBP and Plasmodium VAR2CSA (2019) (0)
Immune Responses to Whole-Organism Blood-Stage Malaria Vaccines (2017) (0)
A novel pathway of haematopoiesis revealed after experimental malaria infection (2010) (0)
Geographic Proximity and the Pro-trade Effect of Migration: State-level Evidence from Mexican Migrants in the United States (2013) (0)
Human antibodies to an epitope in PVDBP block adhesion of plasmodium falciparum placental parasites via cryptic epitopes in VAR2CSA (2019) (0)
A synthetic group A streptococcal vaccine of high purity and broad protective range (2005) (0)
In Vivo Efficacy of a Chimeric Peptide Derived from the Conserved Region of the M Protein against Group C and G Streptococci (2012) (0)
The frequency of circulating T cells reactive to PLP184-209 increases prior to MS relapse and development of new MR1 lesions (1998) (0)
Liposaccharides: Utilisation for Peptide Delivery and for Enhancing Synthetic Peptide Immunogenicity (2001) (0)
Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines (2021) (0)
Analysis of DNA corresponding to group A streptococcal A- and B-regions of M protein by restriction fragment length polymorphism (2006) (0)
Wise to the healthy, wealthy divide (2004) (0)
| New Generation Vaccines | Taylor & Francis Group (2004) (0)
Brian Herbert Kay 1944–2017 (2018) (0)
Identification of a novel Th1 promoting vaccine adjuvant from natural products (P4451) (2013) (0)
Novel lipoamino acid based vaccine adjuvant carrier system (2007) (0)
Liposaccharides for drug and vaccine delivery (2004) (0)
Exposure to low doses of chemically attenuated blood stage malaria parasites rapidly activates CD4+ T cells and induces strain and species transcending immunity (P4477) (2013) (0)
Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy (2018) (0)
Title Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection : CD 1 c + Myeloid Dendritic Cell Maturation Arrest , Induction of the Kynurenine Pathway , and Regulatory T Cell Activation (2018) (0)
BacteremiaVirulent Streptococcal Pyoderma and Vaccine-Mediated Protection against with a CXC Chemokine Protease To Induce A Synthetic M Protein Peptide Synergizes (2015) (0)

This paper list is powered by the following services:

Other Resources About Michael F. Good

en.wikipedia.org

What Schools Are Affiliated With Michael F. Good?

Michael F. Good is affiliated with the following schools: